



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/202,359	05/21/1999	DORIT ARAD	104315	2806

7590 02/01/2005

EUGENIA S.HANSEN
SIDLEY & AUSTIN
717 NORTH HARWOOD
SUITE 3400
DALLAS, TX 752016407

EXAMINER

LUKTON, DAVID

ART UNIT

PAPER NUMBER

1653

DATE MAILED: 02/01/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Response to Rule 312 Communication	Application No.	Applicant(s)	
	09/202,359		
	Examiner	Art Unit	
	David Lukton	1653	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on 23 February 2004 under 37 CFR 1.312 has been considered, and has been:

- a) ☐ entered.
- b) ☐ entered as directed to matters of form not affecting the scope of the invention.
- c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

- d) ☐ disapproved. See explanation below.
- e) ☒ entered in part. See explanation below.


All requested changes will be entered, with the exception of the following two:

1. The amendment to page 28, line 7 which requests that the phrase "non specific inhibition of other" be deleted, and replaced with the phrase "specifically inhibit".
2. The amendment to the paragraph that begins on page 26, line 11.

The first of these (the amendment to page 28, line 7) will not be entered because it constitutes new matter; in the specification as filed, "non-specific inhibition" of enzymes was referred to, whereas the amendment directs that "specific inhibition" of enzymes should be referred to.

The second of these (amendment to the paragraph that begins on page 26, line 11) will not be entered because the paragraph at issue contains a peptide sequence, but does not provide a "SEQ ID NO:" within the text of the paragraph.

D. Lukton 1/28/05



**JON WEBER
SUPERVISORY PATENT EXAMINER**